The ischaemic penumbra

Current Opinion in Neurology

Volumn 14, Issue 1, 2001, Pages 83-88

  Touzani, Omar ^a,b   Roussel, Simon ^a   MacKenzie, Eric T ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

[1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ACETYLTYROSYLVALYLALANYLASPARTYL CHLOROMETHYLKETONE; ADENOSINE TRIPHOSPHATE; BLLL 890CL; CARVEDILOL; CASPASE INHIBITOR; COMPLEMENT INHIBITOR; DISUFENTON SODIUM; GLUTAMATE RECEPTOR AGONIST; GONATOKIN G; KETONE DERIVATIVE; LACTACYSTIN BETA LACTONE; LANICEMINE; MINOCYCLINE; N [4 [4 [(3,4 DIHYDRO 6 HYDROXY 2,5,7,8 TETRAMETHYL 2H 1 BENZOPYRAN 2 YL)CARBONYL] 1 PIPERAZINYL]PHENYL] 2 THIOPHENECARBOXIMIDAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N TERT BUTYL ALPHA PHENYLNITRONE; NEUROSERPIN; OXIDIZING AGENT; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; TIAGABINE; UNCLASSIFIED DRUG;

BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN METABOLISM; BRAIN PROTECTION; DEPOLARIZATION; DRUG MECHANISM; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; TECHNIQUE;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; ELECTROPHYSIOLOGY; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROPROTECTIVE AGENTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035145751     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200102000-00013     Document Type: Review

References (75)

1. Thresholds in cerebral ischemia: The ischemic penumbra
2. Viability thresholds and the penumbra of focal ischemia
3. Three-dimensional image analysis of brain glucose metabolism-blood flow uncoupling and its electrophysiological correlates in the acute ischemic penumbra following middle cerebral artery occlusion
4. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: Evolution of lesion volume and correlation with clinical outcome
5. Ischemic core and penumbra in human stroke
6. Mapping the ischaemic penumbra with PET: Implications for acute stroke treatment
7. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats
8. Sequential studies of severely hypometabolic tissue volumes after permanent middle cerebral artery occlusion. A positron emission tomographic investigation in anesthetized baboons
9. Progressive impairment of brain oxidative metabolism reversed by reperfusion following middle cerebral artery occlusion in anaesthetized baboons
10. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: A correlative PET-CT study with voxel-based data analysis
11. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra
12. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke
13. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole
14. Imaging developing brain infarction
15. Applications of diffusion-perfusion magnetic resonance imaging in acute ischemic stroke
16. New magnetic resonance imaging methods for cerebrovascular disease: Emerging clinical applications
17. Monitoring the initial expansion of focal ischaemic changes by diffusion-weighted MRI using a remote controlled method of occlusion
18. Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat
19. Transient and permanent resolution of ischemic lesions on diffusion-weighted imaging after brief periods of focal ischemia in rats: Correlation with histopathology
20. Secondary decline in apparent diffusion coefficient and neurological outcomes after a short period of focal brain ischemia in rats
21. Diffusion- and perfusion-weighted MR imaging of transient focal cerebral ischaemia in mice
22. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra
23. The ischemic penumbra: Operationally defined by diffusion and perfusion MRI
24. Time course of lesion development in patients with acute stroke: Serial diffusion- and hemodynamic-weighted magnetic resonance imaging
25. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging
26. Diffusion nuclear magnetic resonance imaging in experimental stroke. Correlation with cerebral metabolites
27. Evolution of regional changes in apparent diffusion coefficient during focal ischemia of rat brain: The relationship of quantitative diffusion NMR imaging to reduction in cerebral blood flow and metabolic disturbances
28. Relationship between diffusion weighted MR images, cerebral blood flow, and energy state in experimental brain infarction
29. The temporal evolution of MRI tissue signatures after transient middle cerebral artery occlusion in rat
30. Magnetic resonance imaging assessment of evolving focal cerebral ischemia. Comparison with histopathology in rats
31. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI
32. Combined diffusion and perfusion MRI with correlation to single-photon emission CT in acute ischemic stroke. Ischemic penumbra predicts infarct growth
33. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke
34. Pathobiology of ischaemic stroke: An integrated view
35. The changing landscape of ischaemic brain injury mechanisms
36. Early reperfusion in the anesthetized baboon reduces brain damage following middle cerebral artery occlusion: A quantitative analysis of infarction volume
37. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat
38. Tissue plasminogen activator for acute ischemic stroke
39. One-year follow-up in acute stroke patients treated with rtPA in clinical routine
40. Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia
41. Endothelin receptor antagonist preserves microvascular perfusion and reduces ischemic brain damage following permanent focal ischemia
42. Neuroprotection mediated by changes in the endothelial actin cytoskeleton
43. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment
44. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein
45. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window
46. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia
47. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke
48. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines
49. Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats
50. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis
51. Dose-dependent neuroprotection with tiagabine in a focal cerebral ischemia model in rat
52. Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: In vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies
53. AR-R15896AR reduces cerebral infarction volumes after focal ischemia in cats
54. Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model
55. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury
56. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy
57. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat
58. Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia
59. Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL
60. Estradiol exerts neuroprotective effects when administered after ischemic insult
61. Neuroprotection for acute stroke: Making clinical trials work
62. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?
63. Neuroprotection in acute ischaemic stroke: A tale of for whom the bell tolls?
64. Why do neuroprotective drugs work in animals but not humans?
65. Recommendations for standards regarding preclinical neuroprotective and restorative drug development
66. Dynamics of regional brain metabolism and gene expression after middle cerebral artery occlusion in mice
67. Brain tissue concentrations of ATP, phosphocreatine, lactate, and tissue pH in relation to reduced cerebral blood flow following experimental acute middle cerebral artery occlusion
68. Penumbral tissue alkalosis in focal cerebral ischemia: Relationship to energy metabolism, blood flow, and steady potential
69. Periinfarct depolarizations
70. The nature of penumbral depolarizations following focal cerebral ischemia in the rat
71. Haemodynamic correlates of penumbral depolarization following focal cerebral ischemia
72. Induction of spreading depression in the ischemic hemisphere following experimental middle cerebral artery occlusion: Effect on infarct morphology
73. Repeated negative DC deflections in rat cortex following middle cerebral artery occlusion are abolished by MK-801: Effect on volume of ischemic injury
74. Prevention of periinfarct direct current shifts with glutamate antagonist NBQX following occlusion of the middle cerebral artery in the rat
75. Multiple molecular penumbras after focal cerebral ischemia